Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 1997

View Archived Issues

Tsumura describes agents for dermatitis

Chymase inhibitors from Green Cross

Peptide derivatives with antiinflammatory properties described by U.S. researchers

Rockefeller University discloses antibiotic peptides

Merck describes improved chemotherapeutic agents

Il Yang develops antitumor/immunostimulating proteoglycan

Antiallergic/antiinflammatory agents from Senju

Japanese researchers describe triazole antifungals

Nonantiresorptive substituted bisphosphonate disclosed by Gador

Legionella vaccine described by U.S. researchers

Promising new imaging agent for CNS disorders

Potential anticonvulsant described by CoCensys

Follow-up data reported for Amelorad

First launch for SCLC imaging agent

Promising data reported for fomivirsen

Isis updates activities related to ISIS-2302

Isis previews antisense anticancer program

Another Isis antisense compound to enter clinic

Progress in Bone Care's vitamin D pipeline

Zynaxis sells drug delivery technology

Alza signs licensing agreements for transdermal testesterone products

CEAPRO receives patent coverage for potential vaccine adjuvants

Cypress awarded grant for research related to its PROSORBA Column

Unigene Laboratories reveals bioequivalency results for osteoporosis drug

NIH funds development of antiplatelet agents from Cypress/PRP

RPR's docetaxel now approved in 49 countries

Pegasus completes acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...